No worry about BP paying pennies -- Haven't found a single BP deal with an OTC biotech penny stock in the last decade.
JAMA Oncology reviewers only see what NWBO provides them -- manuscript. protocols and SAPs. Seems other material things were left out like the FDA partial hold of the trial, the details of the external comparators The external comparator selection process is significantly flawed and the deficiencies have been documented in a peer-reviewed criticism that identifies a series of trial deficiencies that bias the outcome in NWBO's favor. Please read the article and it will provide the details: "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?" by Matthias Preusser, Martin J van den Bent https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noac281/6958519?searchresult=1
Market Data 
Markets 
AI
